New hope for kids with tough cancers: first pediatric trial of promising drug duo
NCT ID NCT06104488
Summary
This study is testing the safety of a new two-drug combination (avutometinib and defactinib) for children and young adults (ages 3-30) whose solid tumors have come back or stopped responding to standard treatments. The main goal is to find the highest dose that is safe and causes few or mild side effects. The treatment is specifically for cancers with certain genetic changes in the MAPK pathway or related to NF1/NF2 conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta (Data Collection Only)
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.